Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Status:
Withdrawn

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Patients with chronic HBV infection will receive ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.

Phase 2

Arrowhead Pharmaceuticals